Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UA8967 is a membrane-active anti-tumor agent. Cytotoxicity studies in six pancreatic cancer cell lines, one normal human pancreatic ductal epithelial line and two colon cancer cells showed the IC50s UA8967 ranged from 12–61 μM for exposure times of 72 h. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. UA8967 is observed to affect the plasma membrane.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | UA8967 is a membrane-active anti-tumor agent. Cytotoxicity studies in six pancreatic cancer cell lines, one normal human pancreatic ductal epithelial line and two colon cancer cells showed the IC50s UA8967 ranged from 12–61 μM for exposure times of 72 h. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. UA8967 is observed to affect the plasma membrane. |
分子量 | 305.42 |
分子式 | C20H23N3 |
CAS No. | 17511-50-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
UA8967 17511-50-1 UA 8967 Vivacaine UA-8967 Bupivacaine Hydrochloride Inhibitor inhibitor inhibit